We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
+$9.7M
Cap. Flow %
0.62%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Miscellaneous 90.28%
2 Healthcare 9.38%
3 Communication Services 0.29%
4 Materials 0.04%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FRTX
251
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-185
Closed -$727K
PRTK
252
PUT
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-144
Closed -$551K
ACOR
253
CALL
DELISTED
Acorda Therapeutics
ACOR
– –
-1
Closed -$369K
CCXI
254
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-155
Closed -$86K
SCON
255
DELISTED
Superconductor Technologies Inc.
SCON
– –
-413
Closed -$1M
MDCO
256
CALL
DELISTED
Medicines Co
MDCO
– –
-605
Closed -$2.03M
KERX
257
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-37,890
Closed -$453K
UNXL
258
CALL
DELISTED
Uni-Pixel, Inc.
UNXL
– –
-677
Closed -$1.2M
UNXL
259
PUT
DELISTED
Uni-Pixel, Inc.
UNXL
– –
-998
Closed -$1.77M
ARIA
260
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-31,553
Closed -$170K
NSPH
261
DELISTED
NANOSPHERE INC. COM NEW
NSPH
– –
-17,256
Closed -$690K
SZYM
262
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
– –
-198,350
Closed -$2.14M
SZYM
263
PUT
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
– –
-1,964
Closed -$2.12M
ONCY
264
CALL
DELISTED
ONCOLYTICS BIOTECH INC
ONCY
– –
-100
Closed -$24K
CYBX
265
DELISTED
CYBERONICS INC
CYBX
– –
-5,977
Closed -$303K
CYBX
266
PUT
DELISTED
CYBERONICS INC
CYBX
– –
-1,693
Closed -$8.59M
PCYC
267
CALL
DELISTED
PHARMACYCLICS INC
PCYC
– –
-450
Closed -$6.23M
SLXP
268
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-7,073
Closed -$473K
ELN
269
CALL
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
– –
-1,100
Closed -$1.71M
ASTX
270
CALL
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
– –
-873
Closed -$740K
ASTX
271
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
– –
-99,703
Closed -$845K
ASTX
272
PUT
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
– –
-1,015
Closed -$861K
ONXX
273
CALL
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
– –
-199
Closed -$2.48M
ONXX
274
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
– –
-4,045
Closed -$504K
NWBO
275
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
– –
-978,359
Closed -$3.79M
8 9 10
11
12

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management's Q4 2013 filing shows 83 new, 54 increased, 60 reduced and 62 closed positions. Its largest new stake was Arbutus Biopharma: 519,200 shares worth $4.14M. The largest sale was Vertex Pharmaceuticals, an estimated $23.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, up from 89% a quarter earlier, followed by Healthcare and Communication Services.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.